3,4-CTMP

threo-3,4-dichloromethylphenidate

6Node page

what any key link opens

psx:substance/3-4-ctmp/src/url:208968189852396c

src2026-09-07recordconsumed

derived from · upstream

none recorded

feeds · downstream

usedRevision 1psx:substance/3-4-ctmp/version/1

psx:substance/3-4-ctmp/src/url:208968189852396c
  ├─ used  src/doi:10.1021/jm950697c  Synthesis and Pharmacology of Potential Cocaine Antagonists. 2. Structure-Activity Relationship Studies of Aromatic Ring-Substituted Methylphenidate Analogs
  ├─ used  src/doi:10.3389/fpsyt.2018.00149  In Vitro Neurochemical Assessment of Methylphenidate and Its "Legal High" Analogs 3,4-CTMP and Ethylphenidate in Rat Nucleus Accumbens and Bed Nucleus of the Stria Terminalis
  ├─ used  src/doi:10.1016/j.neuropharm.2017.08.020  Pharmacological profile of methylphenidate-based designer drugs
  ├─ used  src/doi:10.1021/acsomega.3c02997  Chiral Resolution of the Enantiomers of the Slow-Onset Dopamine Reuptake Inhibitor CTDP-32476 and Their Activities
  ├─ used  src/url:ec0798ba86d0bb86  UK Temporary Class Drug Order: Methylphenidate-based NPS (ACMD Report, April 2015)
  ├─ used  src/url:cd066895e93f8534  UNODC Early Warning Advisory: UK temporarily bans five methylphenidate-related NPS (April 2015)
  ├─ used  src/url:fad571eb1571108d  UK Misuse of Drugs Act 1971 (Amendment) Order 2017 - Class B scheduling of methylphenidate NPS
  ├─ used  src/doi:10.1093/jat/bkz052  Use of UPLC-HRMS/MS for In Vitro and In Vivo Metabolite Identification of Three Methylphenidate-derived New Psychoactive Substances
  ├─ used  src/url:99e99262fcb39db7  3,4-Dichloromethylphenidate Experience Report: 'Second Time Around'
  ├─ used  src/doi:10.1073/pnas.2114204120  Persistent binding at dopamine transporters determines sustained psychostimulant effects
  ├─ used  src/doi:10.1093/jat/bkac023  Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A Review
  ├─ used  src/doi:10.1016/j.forsciint.2015.12.045  Seven fatalities associated with ethylphenidate.
  ├─ derived_from  gen/1e500eac-b9c9-4071-ad89-cabb9d8c2904  Generation — pipeline-v5
  ├─ generated_by  pub/7ba3fee3-8094-488a-9682-877fe74508f8  Publication — backfill
    ├─ used  search/7717cb5d-ccc6-489a-b61d-d21b6cf3ad5b  Searched PubChem for "3,4-CTMP"
    ├─ used  search/1e5815e5-7efc-46d5-9fb2-d70a8ad0ff8e  Searched PubMed for "3,4-CTMP dichlorophenyl methylphenidate analog pharmacology"
    ├─ used  search/1e02be1b-d53a-4dec-a5c2-d06e0fcb80dd  Searched OpenAlex for "3,4-CTMP dichlorophenyl phenidate dopamine reuptake inhibitor"
    ├─ used  search/e56f705d-9d23-4efa-8041-b38507e1cd5c  Searched PubMed for "Luethi methylphenidate designer drugs dopamine transporter monoamine"
    ├─ used  search/f4b1df81-fe21-4b29-a075-333a80be99aa  Searched PubMed for "Davidson Raby methylphenidate 3,4-CTMP ethylphenidate nucleus accumbens dopamine voltammetry"
    ├─ used  search/8d83a8cf-fd0c-4de4-a60b-ebd9301f1ac5  Searched WebSearch for "3,4-CTMP dichlorophenyl methylphenidate pharmacology stimulant research chemical"
    ├─ used  search/14b888fc-1f88-4e93-8416-7fde38399d22  Searched WebSearch for "3,4-CTMP legal status UK scheduling controlled substance 2015"
    ├─ used  search/8c52cf0d-43e8-4ce9-97e0-c5ee29ff09a2  Searched ACMD report for "ACMD methylphenidate NPS TCDO 2015"
    ├─ used  search/417ed588-44de-48f8-9e8e-81356d9db85f  Searched PubMed for "UPLC-HRMS methylphenidate-derived new psychoactive substances metabolite identification in vitro in vivo"
    ├─ used  search/8b2138aa-610f-4cd5-8004-101ba505afe2  Searched Frontiers in Psychiatry (PMC) for "Davidson 2018 3,4-CTMP pharmacology in vitro"
    ├─ used  search/6de4e793-6134-4b80-9e8e-1f549fd55af4  Searched WebSearch for "3,4-CTMP binding affinity Ki IC50 DAT SERT NET transporter nanomolar"
    ├─ used  search/25d5df2f-8692-46c0-a1e6-e53c164d6c5b  Searched WebSearch for "3,4-CTMP Europe Sweden Austria Germany banned controlled substance"
    ├─ used  search/5eca9ca8-fcd6-4bc1-ba82-41b56caeae77  Searched Erowid for "3,4-CTMP experience report dose onset duration"
    ├─ used  search/0b10aaa9-0a31-429d-8a29-8fa28f38e7c2  Searched OpenAlex for "Luethi 2018 methylphenidate designer drugs DAT NET SERT 5-HT2B binding affinity in vitro"
    ├─ used  search/e954f140-7af4-46b9-9cd9-f2cb06f4da1e  Searched WebSearch for "3,4-CTMP pharmacokinetics metabolism half-life bioavailability CYP"
    ├─ used  search/88078972-2ffd-4759-b0bc-cf3a5379441a  Searched WebSearch for "3,4-CTMP legal status UK scheduling Class B 2017"
    ├─ used  search/cdc21542-0dca-41df-914f-2bb8f7ecd509  Searched WebSearch for "3,4-CTMP stereochemistry diastereomer threo erythro enantiomer RR RS"
    ├─ used  search/65a9ffe0-52e0-466c-9195-0a7a593062f5  Searched Erowid for "3,4-CTMP dose onset duration effects"
    ├─ used  search/e12ee8af-77c4-49bc-8c0c-02c18784ab6c  Searched Multiple for "Cross-reference of DB seed data vs published/reported findings"
    └─ used  search/f62d6c45-ee52-4832-838f-28f29b998ff3  Searched ClinicalTrials.gov for "3,4-CTMP dichlorophenyl methylphenidate"
├─ used  version/1  Revision 1
  ├─ derived_from  issue/notice@73cf22db1358  Issued notice
  ├─ derived_from  issue/info_card@f3510a9b7614  Issued info_card
  ├─ derived_from  issue/emergency@58d3299a8754  Issued emergency
  ├─ derived_from  issue/info_card@356907db9c3a  Issued info_card
    ├─ used  claim/c48a1de8-5fca-43ce-8d69-efa6da41ac96  Claim in summary — inconclusive  working
    ├─ used  claim/77d86151-9cc1-4506-8054-de46a390ba12  Claim in summary — inconclusive  working
    ├─ used  claim/7a7322b5-c5e7-4c2d-9a7c-3a50f4da85a3  Claim in summary — inconclusive  working
    ├─ used  claim/bc63bf63-f64e-45f8-9ef4-5da50322281d  Claim in safety — inconclusive  working
    ├─ used  claim/caabcb19-1e33-4fbe-bad5-4b8c0c3bb18f  Claim in history — inconclusive  working
    ├─ used  claim/298f698f-70e7-4fc0-aad5-3ddfa7d5e128  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/c39fa12a-5c32-4fc2-887e-853b73bdcda7  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/e66e36a1-0f5f-4b56-82ec-ce24b806967d  Claim in clinical-evidence — inconclusive  working
    ├─ used  claim/f9add27e-16eb-445a-b214-a58ff4ca8fb2  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/077c6e00-faac-44a5-bc0e-dfe41b302bb5  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/67a2aa44-d883-428a-9870-ebeefbcc36ce  Claim in summary — supported
    ├─ used  claim/0e311ca2-8071-430d-9f38-8aabfd238362  Claim in summary — inconclusive  working
    ├─ used  claim/e9122fcc-a264-4d7e-9e77-ef7073345507  Claim in safety — inconclusive  working
    ├─ used  claim/e03ca3b4-164d-4901-ac96-7c439d0ccfd1  Claim in history — supported
    ├─ used  claim/385c6d28-0d02-4659-bbbf-c985df0fc34b  Claim in comparative-pharmacology — supported
    ├─ used  claim/9faf2823-305d-4486-af0c-625f3eba8807  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/15bad5d3-51c5-4c67-950f-380a9e957deb  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/5a9d8b56-89f1-42c7-9ed7-29e7107db092  Claim in neuroscience — supported
    ├─ used  claim/071824ac-f8f3-42a9-9f13-a9e73d1e1576  Claim in summary — inconclusive  working
    ├─ used  claim/0af51ef1-93f3-4ebd-bdf6-f96bfe057d9d  Claim in summary — inconclusive  working
    ├─ used  claim/7cddaf0d-5c34-485c-8ab0-2a67f9a4a964  Claim in pharmacology — inconclusive  working
    ├─ used  claim/5f0ca4c1-e90d-40e0-8d89-8a0f7d4490a7  Claim in pharmacology — inconclusive  working
    ├─ used  claim/42ad2a56-4d65-47cf-b808-8bfcfb572858  Claim in pharmacology — inconclusive  working
    ├─ used  claim/796ade03-68b0-48ff-813e-ec2b1ac498b3  Claim in pharmacology — inconclusive  working
    ├─ used  claim/767a6fa5-499e-48f0-9ab4-e5df148b3d2d  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/d8664010-a375-487b-8cf4-e893db02c4b2  Claim in safety — inconclusive  working
    ├─ used  claim/ea34e7b8-2bb0-408c-b9fe-5147b6f41dc5  Claim in safety — inconclusive  working
    ├─ used  claim/fcda9080-d891-4780-96cf-759899ef37c3  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/c5cb300c-b87a-44e2-8427-854094968e9e  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/bb7fbda0-2b5a-4da2-b0cd-349fa37a1721  Claim in neuroscience — inconclusive  working
    ├─ used  claim/92ab7f0e-a39e-4173-b68f-e7a9dc0ba1d5  Claim in summary — supported
    ├─ used  claim/a3f369a5-2ede-4e06-bfbc-389e0a0a97ea  Claim in history — supported
    ├─ used  claim/4d781c5e-9ae7-441d-850f-f51851e05b5b  Claim in clinical-evidence — inconclusive  working
    ├─ used  claim/8b1068da-a5e2-413b-9afe-5ffc4a5a17e4  Claim in comparative-pharmacology — supported
    ├─ used  claim/253c1e50-e6ad-4a05-9216-0d8e7a5b4a2e  Claim in pharmacology — supported
    ├─ used  claim/ada0c6eb-4283-4694-bbc1-d7aef3801639  Claim in pharmacokinetic-detail — supported
    ├─ used  claim/7fbd94a7-431b-4715-b292-9c23988dbd4e  Claim in pharmacokinetic-detail — supported
    ├─ used  claim/11454c34-3e0e-42f9-b224-a189fc5a05bc  Claim in neuroscience — supported
    ├─ used  claim/7ccdacbb-4ef8-4f91-8ce1-9979b6c58d84  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/3088e9e8-e74b-407f-9679-71ba19fb96ff  Claim in safety — inconclusive  working
    ├─ used  claim/c6d62b0e-c8bf-4a79-a8aa-0fa55ba20754  Claim in comparative-pharmacology — supported
      ├─ informed_by  section/summary.full@1
      ├─ informed_by  section/safety.full@1
      ├─ informed_by  section/history.full@1
      ├─ informed_by  section/receptor-pharmacology.full@1
      ├─ informed_by  section/clinical-evidence.full@1
      ├─ informed_by  section/comparative-pharmacology.full@1
      ├─ informed_by  section/neuroscience.full@1
      ├─ informed_by  section/pharmacology.full@1
      └─ informed_by  section/pharmacokinetic-detail.full@1

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

138 with DOI

0 strong · 8 moderate · 5 weak

Compilations

22026-05-12T20:57:31.448Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

32last ruled 2026-06-04

0 awaiting a ruling

Issued documents

42026-10-19T20:29:31.236Z

notice · info card · emergency

Searches

202 with no results

queries and counts on the build

Claims checked

4112 supported

12 supported · 29 not

Correspondence

0received

consent field ships in Phase 4

Edges

160

derivations recorded for this entity

Complete over 13 sources, 2 compilations, and 32 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/3-4-ctmp/archive

2Build

one panel per compilation run

generation run 2026-05-11

12 min failedmodel not recordedplan not recordedrun/21f1c89b…

research

no artifact

draft

no artifact

audit

no artifact

verify

no artifact

simplify

no artifact

publish

no artifact

Selection

results seen0

selected by the model0

consumed as sources13

Verification

claims checked0

supported0

partially supported0

not supported0

inconclusive0

record
seen / partial
working

The model's own caveats

none raised on this run

Reproduce

inputs: 13 source keys (listed under Sources)
plan: not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model: not recorded
streams: none — agent transcripts are persisted from 2026-09 onward

generation run 2026-05-12

61 min completedmodel pipeline-v5plan not recordedrun/4c3dc63a…

Selection

results seen86

selected by the model23

consumed as sources13

Verification

claims checked41

supported12

partially supported0

not supported0

inconclusive29

record
seen / partial
working

The model's own caveats

sparse_evidence
structural_inference
sparse_evidence

Reproduce

inputs: 13 source keys (listed under Sources)
plan: not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model: pipeline-v5
streams: none — agent transcripts are persisted from 2026-09 onward

20 searches — query, source, results, what was kept and why

20 searches for this run
#	source	query	seen	kept	rationale
1	WebSearch	3,4-CTMP legal status UK scheduling controlled substance 2015	10	2	Legal status data confirmed from official sources
2	OpenAlex	3,4-CTMP dichlorophenyl phenidate dopamine reuptake inhibitor	1	1	Relevant NPS review including phenidate class
3	PubMed · absence	3,4-CTMP dichlorophenyl methylphenidate analog pharmacology	0	—	—
4	PubChem	3,4-CTMP	1	1	Single unique match for 3,4-CTMP; all chemical identity data confirmed
5	ACMD report	ACMD methylphenidate NPS TCDO 2015	1	—	Could not extract text
6	WebSearch	3,4-CTMP dichlorophenyl methylphenidate pharmacology stimulant research chemical	10	4	Multiple background sources confirming key facts about 3,4-CTMP
7	PubMed	Luethi methylphenidate designer drugs dopamine transporter monoamine	1	1	Key in vitro pharmacology paper on phenidate NPS class including 3,4-CTMP
8	PubMed	Davidson Raby methylphenidate 3,4-CTMP ethylphenidate nucleus accumbens dopamine voltammetry	1	1	Only published in vitro study specific to 3,4-CTMP neurochemistry
9	OpenAlex	Luethi 2018 methylphenidate designer drugs DAT NET SERT 5-HT2B binding affinity in vitro	2	1	Mechanistic context for 3,4-CTMP DAT binding kinetics
10	WebSearch	3,4-CTMP Europe Sweden Austria Germany banned controlled substance	10	1	Comprehensive multi-jurisdiction legal status data
11	PubMed	UPLC-HRMS methylphenidate-derived new psychoactive substances metabolite identification in vitro in vivo	1	1	Only published metabolism study for 3,4-CTMP
12	Erowid	3,4-CTMP experience report dose onset duration	1	1	Primary user experience data supporting onset/duration characterization
13	WebSearch	3,4-CTMP binding affinity Ki IC50 DAT SERT NET transporter nanomolar	10	1	Key binding affinity values for pharmacology section
14	Frontiers in Psychiatry (PMC)	Davidson 2018 3,4-CTMP pharmacology in vitro	1	1	Primary pharmacology paper directly measuring 3,4-CTMP effects
15	Erowid	3,4-CTMP dose onset duration effects	1	1	Only detailed primary user experience data found; onset data contradicts DB seed value
16	WebSearch	3,4-CTMP legal status UK scheduling Class B 2017	10	2	Comprehensive legal status data across jurisdictions
17	WebSearch	3,4-CTMP stereochemistry diastereomer threo erythro enantiomer RR RS	10	1	Stereochemistry clarification for article
18	Multiple	Cross-reference of DB seed data vs published/reported findings	5	1	Quality control cross-referencing for generation agent
19	WebSearch	3,4-CTMP pharmacokinetics metabolism half-life bioavailability CYP	10	2	Key pharmacokinetics finding - only published metabolism data for 3,4-CTMP
20	ClinicalTrials.gov · absence	3,4-CTMP dichlorophenyl methylphenidate	0	—	Confirmed no clinical trials exist for this substance

41 claims by section — every cited sentence, checked against its source

comparative-pharmacology8 · 3 ok

Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
The closest comparator is ethylphenidate, for which Maskell et al. (2016) documented 7 fatalities in the UK between February 2013 and January 2015, with blood concentrations of 0.026–2.18 mg/L; one death was attributed solely to ethylphenidate toxicity, four to mixed-drug toxicitysupported
7 deaths with EPH in postmortem blood Feb 2013-Jan 2015. One sole EPH toxicity; 4 mixed drug toxicity; 2 hanging. Concentrations 0.026-2.18 mg/L in femoral blood. j.forsciint.2015.12.045
Davidson et al. (2018) directly compared 3,4-CTMP, ethylphenidate, and methylphenidate using fast cyclic voltammetry in adolescent male rat brain slices.supported
3,4-CTMP (0.1 and 1 uM) increased evoked dopamine and noradrenaline efflux by ~6-fold and 2-fold, respectively, in rat brain slices. FCV used to measure DAT/NET effects. fpsyt.2018.00149
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
This is consistent with pharmacokinetic theories of abuse potential: compounds with slow onset of DAT occupancy produce less subjective "rush" and weaker conditioned reinforcement than rapid-onset inhibitors such as cocainesupported
Slow-onset activity is important for limited abuse potential in stimulants. acsomega.3c02997
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

summary8 · 2 ok

Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
The compound appeared on UK research chemical markets in 2013 and was subsequently scheduled in multiple jurisdictionssupported
3,4-CTMP appeared on the UK drug market in 2013. fpsyt.2018.00149
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Despite its high potency, the slow oral onset (2–4 hours) tempers reinforcing effects relative to faster-acting DAT inhibitors.supported
Slow-onset activity is important for limited abuse potential in stimulants. acsomega.3c02997
Claim in summary — inconclusiveinconclusiveworking →

pharmacology5 · 1 ok

Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Manier et al. (2020) identified 7 phase I metabolites and no phase II metabolites using UHPLC-HRMS/MSsupported
3,4-CTMP: 7 phase I metabolites, no phase II metabolites. Primarily hydrolyzed to carboxy metabolites. bkz052

receptor-pharmacology5 · 0 ok

Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

safety5 · 0 ok

Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →

history3 · 2 ok

Claim in history — inconclusiveinconclusiveworking →
The research program was motivated by the cocaine antagonist hypothesis: a long-acting DAT inhibitor with slow onset might attenuate cocaine craving without producing the rapid reinforcing effects that sustain cocaine self-administrationsupported
Slow-onset activity is important for limited abuse potential in stimulants. Related to methylphenidate SAR research. acsomega.3c02997
3,4-CTMP appeared on the UK research chemical market in 2013, marketed as a "designer drug" in powder and pellet form via online vendorssupported
3,4-CTMP appeared on the UK drug market in 2013. fpsyt.2018.00149

neuroscience3 · 2 ok

Davidson et al. (2018) demonstrated that 3,4-CTMP at 0.1–1 µM produces a ~6-fold increase in evoked dopamine efflux in rat nucleus accumbens slices — a magnitude exceeding that produced by 100-fold higher concentrations of the parent compoundsupported
3,4-CTMP (0.1 and 1 uM) increased evoked dopamine and noradrenaline efflux by ~6-fold and 2-fold, respectively, in rat brain slices. fpsyt.2018.00149
Claim in neuroscience — inconclusiveinconclusiveworking →
DAT binding kinetics: Does 3,4-CTMP exhibit slow dissociation from DAT (low koff), and does this contribute to its prolonged duration independent of metabolic resistance? Niello et al. (2023) established that DAT binding persistence determines sustained psychostimulant effects, but this has not been directly measured for 3,4-CTMP.supported
Drug-binding kinetics at DAT determine in vivo psychostimulant duration. Slow off-rate (koff) from DAT predicts more persistent in vivo effects vs cocaine and methylphenidate. pnas.2114204120

clinical-evidence2 · 0 ok

Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →

pharmacokinetic-detail2 · 2 ok

Manier et al. (2020) conducted the only published metabolism study of 3,4-CTMP, using UHPLC-HRMS/MS analysis of in vivo rat urine samples and in vitro incubations with pooled human liver S9 fraction.supported
Metabolite identification of IPH, 4-FMPH and 3,4-CTMP using UHPLC-HRMS/MS. Rat urine + human S9 fraction. bkz052
Niello et al. (2023) demonstrated that persistent binding at the dopamine transporter — rather than plasma half-life alone — determines sustained psychostimulant effectssupported
Drug-binding kinetics at DAT determine in vivo psychostimulant duration. Slow off-rate (koff) from DAT predicts more persistent in vivo effects vs cocaine and methylphenidate. pnas.2114204120

3Sources

13 consumed · sorted by year · feeds = sections resting on it

Sources
year	source	tier	status	feeds
2024	3,4-Dichloromethylphenidate - PubChem Compound CID 44296390National Center for Biotechnology Information (NCBI)url:208968189852396c	moderate	consumed	cited only
2023	Chiral Resolution of the Enantiomers of the Slow-Onset Dopamine Reuptake Inhibitor CTDP-32476 and Their ActivitiesFroimowitz M, Taboada R, Poulos ZJ, Rainone DJ, Imler GH, Gardner EL, Kelley CJ · ACS Omegadoi:10.1021/acsomega.3c02997	moderate	consumed	4 sections
2023	Persistent binding at dopamine transporters determines sustained psychostimulant effectsNiello M, Sideromenos S, Gradisch R, O'Shea R, et al. · Proceedings of the National Academy of Sciencesdoi:10.1073/pnas.2114204120	moderate	consumed	2 sections
2022	Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A ReviewMohr ALA, Logan BK, Fogarty MF, Krotulski AJ, Papsun DM, et al. · Journal of Analytical Toxicologydoi:10.1093/jat/bkac023	moderate	consumed	2 sections
2020	Use of UPLC-HRMS/MS for In Vitro and In Vivo Metabolite Identification of Three Methylphenidate-derived New Psychoactive SubstancesManier SK, Niedermeier S, Schäper J, Meyer MR · Journal of Analytical Toxicologydoi:10.1093/jat/bkz052	moderate	consumed	2 sections
2018	In Vitro Neurochemical Assessment of Methylphenidate and Its "Legal High" Analogs 3,4-CTMP and Ethylphenidate in Rat Nucleus Accumbens and Bed Nucleus of the Stria TerminalisDavidson C, Raby CAR, Barrese V, Ramsey J · Frontiers in Psychiatrydoi:10.3389/fpsyt.2018.00149	moderate	consumed	5 sections
2018	Pharmacological profile of methylphenidate-based designer drugsLuethi D, Kaeser PJ, Brandt SD, Krähenbuhl S, Hoener MC, Liechti ME · Neuropharmacologydoi:10.1016/j.neuropharm.2017.08.020	moderate	consumed	5 sections
2017	UK Misuse of Drugs Act 1971 (Amendment) Order 2017 - Class B scheduling of methylphenidate NPSUK Home Officeurl:fad571eb1571108d	weak	consumed	cited only
2016	Seven fatalities associated with ethylphenidate.Maskell PD, Smith PR, Cole R, Hikin L, Morley SR · Forensic Science Internationaldoi:10.1016/j.forsciint.2015.12.045	weak	consumed	1 section
2015	UK Temporary Class Drug Order: Methylphenidate-based NPS (ACMD Report, April 2015)Advisory Council on the Misuse of Drugs (ACMD)url:ec0798ba86d0bb86	weak	consumed	cited only
2015	UNODC Early Warning Advisory: UK temporarily bans five methylphenidate-related NPS (April 2015)UNODCurl:cd066895e93f8534	weak	consumed	cited only
2014	3,4-Dichloromethylphenidate Experience Report: 'Second Time Around'Anonymous (Erowid user)url:99e99262fcb39db7	weak	consumed	cited only
1996	Synthesis and Pharmacology of Potential Cocaine Antagonists. 2. Structure-Activity Relationship Studies of Aromatic Ring-Substituted Methylphenidate AnalogsDeutsch H, Shi Q, Gruszecka-Kowalik E, Schweri M · Journal of Medicinal Chemistrydoi:10.1021/jm950697c	moderate	consumed	6 sections
—	Searched ClinicalTrials.gov for "3,4-CTMP dichlorophenyl methylphenidate" — no resultsabsence		no results	—
—	Searched PubMed for "3,4-CTMP dichlorophenyl methylphenidate analog pharmacology" — no resultsabsence		no results	—

4Docket

one filing per activity — decisions, correspondence, reports

0012026-05-12revisionRevision 1
Initial LLM generation (v5 pipeline, wiki, prose phase)
psx:substance/3-4-ctmp/version/1
0022026-06-04proposal30 value proposals approved together
one review action inferred from a shared reviewer and instant — the graph records one activity per proposal
30 items in this filing
- contraindication · other
- contraindication · neurological
- contraindication · cardiovascular
- contraindication · psychiatric
- contraindication · psychiatric
- contraindication · hepatic
- contraindication · other
- contraindication · pregnancy_breastfeeding
- dose_tier · threshold
- dose_tier · light
- dose_tier · common
- dose_tier · strong
- dose_tier · heavy
- timeline · oral · onset
- timeline · oral · come_up
- timeline · oral · peak
- timeline · oral · resolution
- timeline · oral · afterglow
- toxicity
- dependence · full
- withdrawal
- tolerance
- dosage · oral
- duration · oral · onset
- duration · oral · come_up
- duration · oral · peak
- duration · oral · offset
- duration · oral · total
- duration · oral · aftereffects
psx:substance/3-4-ctmp/proposal/contraindication/3ba0edf6-c1ea-4437-a5c8-5687f1a646ed
0032026-06-04publicationPublication — backfill
psx:substance/3-4-ctmp/pub/7ba3fee3-8094-488a-9682-877fe74508f8

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
document	content hash	issued	from version	superseded
info_card	356907db9c3aafc83bba839a…	2026-10-19 20:29	Revision 1	current
emergency	58d3299a8754d788e3d74c0e…	2026-09-04 04:27	Revision 1	current
info_card	f3510a9b76148185a09fbe8e…	2026-09-04 04:27	Revision 1	superseded2026-10-19
notice	73cf22db1358416d526aa30d…	2026-09-04 04:27	Revision 1	current

3,4-CTMP

6Node page

derived from · upstream

feeds · downstream

1Provenance card

2Build

generation run 2026-05-11

research→

draft→

audit→

verify→

simplify→

publish

Selection

Verification

The model's own caveats

Reproduce

generation run 2026-05-12

research→

draft→

audit→

verify→

simplify→

publish

Selection

Verification

The model's own caveats

Reproduce

3Sources

4Docket

5Issued documents

research

draft

audit

verify

simplify

research

draft

audit

verify

simplify